Submission of Advertisement clipping of the Extract of the Audited Standalone and Consolidated Financial Result of the company for the Quarter and Year ended 31-03-2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx has submitted to BSE the newspaper advertisement clippings (published in Business Standard, Mumbai and Swadesh, Bhopal on 29 May 2025) of its audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025, which were approved by the Board on 28 May 2025. On a standalone basis, FY25 income from operations rose to Rs 1,055.55 lakh from Rs 830.42 lakh in FY24, while net profit after tax grew to Rs 475.60 lakh (FY24: Rs 342.14 lakh), up around 39% year-on-year. Consolidated FY25 revenue stood at Rs 1,115.52 lakh and net profit after tax at Rs 476.91 lakh versus Rs 321.01 lakh in FY24, a jump of roughly 49%. Standalone basic and diluted EPS for FY25 came in at Rs 55.51, compared with Rs 39.93 in FY24. Reserves (excluding revaluation reserve) stood at Rs 21,921.24 lakh standalone and Rs 21,690.58 lakh consolidated as on 31 March 2025.
This is a routine Reg 47 compliance filing confirming publication of already-approved results, so it is unlikely to move the stock on its own. However, the embedded results show healthy double-digit YoY growth in both standalone and consolidated profits, which is a positive signal for shareholders.